Navigation path

EUROVAC I


HIV/AIDS

European Vaccine Effort Against HIV/AIDS
Framework programme:
5
Project number:
QLK2-CT-1999-01321
EC contribution:
€ 8 845 000
Duration:
36 months
Type:
RS
Starting date:
1 January 2000

Keywords: AIDS vaccine; phase I HIV vaccine trial ; vaccinia virus recombinant vaccine vectors; HIV-1 subtypes B and C; prime-boost HIV vaccine

Summary:

The EuroVac cluster has two main objectives. The first is to conduct and analyse a phase I randomised study in healthy, HIV-1 seronegative human volunteers at low risk of infection, using a recombinant pox virus prime-recombinant env glycoprotein boost regimen. The second objective is to improve the first generation vaccine on the basis of experiments in non-human primates. The work will specifically focus on the immunogenicity of two different vaccinia virus recombinants (MVA vs NYVAC) with identical HIV-1 subtype B gag-pol-nef and env antigens and of identical vaccinia virus recombinant with antigens of different subtypes (NYVAC-B vs NYVAC-C) for priming, and of homologous (NYVAC-C + rgp120 subtype C) versus heterologous (NYVAC-B + rgp120 subtype C) protein for boosting.

[+] Read More